Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of death and disability globally. Both cigarette smoking and HIV have been identified as independent risk factors for COPD. We used data from the strategic timing of antiretroviral treatment (START) Pulmonary Substudy to quantify the impact of smoking on rate of lung function decline in HIV.
INTRODUCTION
In the combination antiretroviral treatment (ART) era, mortality among HIV-positive individuals has shifted away from AIDS-related causes toward non-AIDS malignancies, cardiovascular disease, liver disease, and nonopportunistic infections. 1, 2 Smoking has been associated with increased allcause and non-AIDS-related mortality among HIV-positive individuals, and life-years lost to smoking may rival life-years lost to HIV. 3 HIV-positive individuals are more likely to smoke, less likely to quit smoking, and may face unique barriers to smoking cessation. 4, 5 Chronic obstructive pulmonary disease (COPD) is among the leading causes of death and disability worldwide. Although smoking is clearly the most important risk factor for the development of COPD, 6, 7 HIV infection has also been associated with an increased risk of COPD, decreased lung function, and respiratory symptoms. [7] [8] [9] [10] There are numerous proposed mechanisms for the increased rates of COPD among HIV-positive individuals including changes in immune function, direct viral effects, and susceptibility to infection. 11 Smoking also likely contributes to COPD risk in HIVpositive smokers, and the effect of smoking on COPD development may be greater among HIV-positive smokers than among HIV-negative smokers. [11] [12] [13] COPD is defined by lung function testing showing expiratory airflow limitation, where the ratio of forced expiratory volume in 1 second (FEV 1 )/forced vital capacity (FVC) is low. FEV 1 decreases with normal aging, but faster decline in FEV 1 is a marker of COPD susceptibility and has been associated with increased respiratory and all-cause mortality. 14, 15 There are few contemporary data regarding FEV 1 decline in HIV because most longitudinal pulmonary function data in HIV-positive persons have come from small and/or single-center samples with limited follow-up time. [16] [17] [18] [19] We addressed this knowledge gap using data from the Strategic Timing of ART (START) Pulmonary Substudy and aimed to investigate the effect of smoking on lung function decline and self-reported respiratory health status among HIV-positive individuals.
MATERIALS AND METHODS

Study Design and Participants
The START Trial and the Pulmonary Substudy
The Strategic Timing of Antiretroviral Treatment (START) trial enrolled 4685 asymptomatic HIV-positive adults, naive to ART with baseline CD4 + T-cell counts .500 cells per mm 3 . Participants were randomized to initiation of ART immediately or at a CD4 + T-cell count of 350 cells per mm 3 . The study was unblinded early because of immediate ART reducing both AIDS and non-AIDS events. 20 The START Pulmonary Substudy was nested within the START trial and enrolled 1026 participants from 80 sites in 20 countries. Additional entry criteria for the substudy are fully outlined in previous publications but included age of at least 25 years, no recent respiratory illness, no use of asthma medications, and no contraindications to postbronchodilator spirometry. 21, 22 The substudy primary outcome was annual rate of FEV 1 decline, expressed as the FEV 1 slope. No significant difference was found in FEV 1 slope in those assigned to immediate vs deferred ART. 22 
Current Analysis
In this analysis of the effects of smoking, we included individuals from the START Pulmonary Substudy who contributed at least 2 spirometry measures during the study. We additionally restricted this analysis to spirometry data meeting quality control review criteria as established by international spirometry standards. 23 
Procedures
Trial procedures are fully outlined in previous publications. [20] [21] [22] In brief, postbronchodilator spirometry was performed before randomization and once per year during follow-up. Spirometry was performed using the EasyOne ultrasonic flow device (ndd Medical, Andover, MA), and all spirometry was centrally reviewed and scored by author K.M. K. Repeat spirometry was requested when testing did not meet published quality standards. The first participant was enrolled in March 2010; the data were unblinded in May 2015; and follow-up continued through the end of December 2016. Global Lung Function Initiative 2012 normative equations were used to determine predicted FEV 1 and the fifth percentile [lower limit of normal (LLN)] for FEV 1 / FVC. 24 COPD is defined by airflow obstruction on spirometry, as either FEV 1 /FVC less than the LLN (the fifth percentile of predicted) or less than a fixed ratio of 0.7. 25 We analyzed our results using both competing definitions.
A detailed smoking history was obtained at baseline. Self-reported smoking status was then assessed at annual follow-up visits. Current smoking was defined as having smoked greater than 10 cigarettes in the past 30 days.
The St. George's Respiratory Questionnaire for COPD (SGRQ-C) was administered in all countries where a harmonized linguistic and cultural translation was either available or could be performed in a timely manner before site initiation for the randomized trial.
Statistical Analysis
FEV 1 slopes for baseline smokers and nonsmokers were estimated and compared using a repeated-measures mixed model with random intercept and slope and autoregressive (1) covariance matrix adjusted for the treatment group (immediate vs deferred treatment arm of START), age, sex, race, and baseline COPD (FEV 1 /FVC , LLN). Previous work in this cohort showed that region was associated with cross-sectional FEV 1 , and thus, we also adjusted for region. 21 Data from the Lung Health Study showed that with smoking cessation, FEV 1 slope tends to be similar to that in nonsmokers. 26 Therefore, we analyzed former smokers with the nonsmoker group in the primary analyses.
In secondary analyses, we accounted for changes in smoking status during follow-up by censoring lung function data at the first visit where participants reported a change in smoking status from baseline. We also categorized persons as continuous smokers (consistently reported smoking at every study visit), intermittent smokers (reported differing smoking status at 2 or more visits), and sustained nonsmokers (consistently reported not smoking at each study visit), and compared FEV 1 slopes among those 3 groups using pairwise t tests.
Although there is no consensus definition of rapid lung function decline, decline of more than 40 mL/yr is commonly used. 14, 27, 28 We compared the proportion of rapid decliners between baseline smokers and nonsmokers using this 40 mL/ yr definition and also explored other definitions of 50 and 60 mL/yr using x 2 tests.
To evaluate for incident COPD, we excluded those with COPD at baseline and compared the frequency of any followup spirometry demonstrating COPD, using the Fisher exact test with stratification by sex.
Changes from baseline in the St. Georges Respiratory Questionnaire were modeled using a repeated-measures (months 12, 24, 36, 48, 60, and 72) mixed model for change in score from baseline, adjusted for baseline score. All analyses were performed using SAS 9.4 (Cary, NC).
RESULTS
Of 1026 START Pulmonary Substudy participants, 915 (89%) were included in the primary slope analysis (247 smokers and 668 nonsmokers). One hundred eleven were excluded because of not having any follow-up spirometry tests (21 smokers and 43 nonsmokers) or not meeting spirometry quality control criteria (23 smokers and 24 nonsmokers) (Fig. 1 ). Compared to those included in the analysis, participants who were excluded were more likely to be white (41.4% vs 32.6%), less likely to be Asian (1.8% vs 11.3%), less likely to report sexual contact with a person of the opposite sex (35.1% vs 44.9%), and more likely to be current smokers (39.6% vs 27.0%). Those included and excluded in this analysis were similar in regards to baseline CD4 + count, HIV-RNA, and lung function.
Baseline characteristics of smokers and nonsmokers are shown in Table 1 . Smokers and nonsmokers were similar in baseline age (median 36 years), but smokers were more likely to be white, male, from Europe/Israel/Australia, and report male sexual contact with persons of same sex (Table 1) . Nonsmokers were more likely to be from Africa. Years since HIV diagnosis were similar between smokers and nonsmokers. Laboratory HIV parameters including CD4 + T-cell count, CD8 + T-cell count, CD4/CD8 ratio, and nadir CD4 + Tcell count were similar, but smokers were less likely to have HIV-RNA ,400 copies per milliliter (4.5% vs 11.4%).
15.1% of baseline nonsmokers were former smokers who reported an average of 4.0 (1.0-10.0) pack-years of smoking. Baseline smokers had an average of 7.0 (2.8-15.0) pack-years of smoking and were smoking 10 (5-18) cigarettes per day at baseline. Medical history was similar between smokers and nonsmokers.
Baseline SGRQ scores among smokers were higher (indicating worse health status) than nonsmokers for total score (9.0 vs 5.8), symptom domain (17.9 vs 11.1), and activity domain (13.3 vs 7.0). Baseline percent predicted FEV 1 was slightly lower in smokers than in nonsmokers (94.2% vs 96.9%). Smokers had a higher prevalence of baseline COPD (12.1% vs 4.9% by the LLN COPD definition; 10.9% vs 3.7% by the fixed-ratio definition).
Median follow-up time was 3.9 years [interquartile range (IQR): 3.0-4.6] and was similar in smokers and nonsmokers.
Baseline smokers had a statistically and clinically significantly faster average rate of decline in FEV 1 than nonsmokers in our primary analysis {238.3 mL/yr vs 225.1 mL/yr; difference of 213.2 mL/yr [95% confidence interval (CI): 223.6 to 22.7]; P = 0.013} (Table 2) .
In secondary analyses censoring spirometry data at the time of any reported change in smoking status from the baseline visit, we found that among those who were smokers at baseline 89 (36.0%) self-reported having quit smoking at one or more follow-up visits, whereas 45 (6.7%) nonsmokers at baseline subsequently reporting smoking at one or more follow-up visits. In this analysis, smokers had a faster average rate of FEV 1 decline compared with nonsmokers with a difference of 214.5 mL/yr (95% CI: 226.3 to 22.8; P = 0.015) ( Table 2) .
In an additional secondary analysis, we categorized persons as continuous smokers (n = 158), intermittent smokers (n = 134), or sustained nonsmokers (n = 623). Continuous smokers had a faster average rate of FEV 1 decline than sustained nonsmokers [difference of 217.9 mL/yr (95% CI: 230.6 to 25.2); P = 0.006]. There was no statistically significant difference between continuous smokers and intermittent smokers nor between intermittent smokers and sustained nonsmokers (Fig. 2) .
Rapid Decline in Lung Function
The proportion of rapid lung function decliners in baseline smokers compared with nonsmokers showed a trend toward statistical significance when using the standard cutoff of more than 40 mL/yr decline (46.6% vs 39.4%; P = 0.09); stronger differences emerged when using more extreme definitions of rapid decline such as 50 mL/yr (P = 0.06) or 60 mL/yr (P = 0.002) ( Table 3) . 
Incident COPD
After excluding persons with COPD at baseline, baseline smokers seemed more likely to meet spirometry criteria for COPD (defined as FEV 1 /FVC , LLN) during follow-up compared with nonsmokers, although this difference did not meet statistical significance (9.7% vs 5.8%, respectively; P = 0.061). Using the fixed-ratio definition of COPD (FEV 1 /FVC , 0.7) also did not demonstrate a statistically significant difference (7.7% vs 5.0%; P = 0.108).
Respiratory Health Status
Baseline smokers demonstrated a trend toward worse SGRQ total scores over time compared with nonsmokers (difference of 1.0 points; 95% CI: 20.1 to +2.1; P = 0.070), but this did not meet statistical significance and the 95% CI excluded the minimal clinically important difference in SGRQ total score of 4 points (Table 4) . 29 There was a statistically significant worsening in the SGRQ symptom component in baseline smokers compared with nonsmokers (difference of 3.2 points; 95% CI: 1.5 to 4.9; P = ,0.001). There is no established minimal clinically important difference for SGRQ component subscores. There was no significant difference in mean change from baseline in the impacts or activity scores.
DISCUSSION
We found that HIV-positive individuals who smoke have a faster rate of lung function decline than HIV-positive individuals who do not smoke, thus increasing the subsequent risk of the development of COPD. Although this finding is not surprising, longitudinal lung function has not been well studied in HIV, and our multicenter, international sample with multiple measurements of lung function over approximately 4 years allowed us to uniquely address this important outcome. Our data reinforce the negative health impact of smoking in HIV.
There are little contemporary longitudinal data on lung function decline in HIV-positive individuals and what data there are come from small and/or single-center studies. In a retrospective single-center study of 79 patients receiving aerosolized pentamidine between 1989 and 2001 in Toronto, smokers (n = 38) had a faster rate of FEV 1 decline than nonsmokers (n = 41) (260 mL/yr vs 230 mL/yr, respectively), but the difference was not statistically significant, likely due to insufficient power. 18 In a single-center cohort (2007-2010) of 316 HIV-positive IV drug users in Baltimore, 84% of whom were active smokers, high HIV-RNA levels and low CD4 + count were associated with faster FEV 1 decline, but the effect of smoking was not reported and such an analysis would likely have been underpowered, because of the low prevalence of nonsmokers. 17 A single-center study in Soweto (n = 619, 2008-2011) found a trend toward faster FEV 1 decline in smokers than nonsmokers, but the difference was not statistically significant (17 mL/yr difference; 95% CI: 236 to +1 mL/yr), perhaps due to both the small number of smokers (8% current smokers and 22% former smokers) and limited median follow-up time of 18 months. 19 Our larger (n = 915) and longer-duration (median follow-up of 3.9 years) study had more statistical power than the Soweto study, and we notably found similar point estimates for the effect of smoking on FEV 1 decline. These data fill in an important knowledge gap regarding the effect of smoking on lung function decline in HIV.
We found that 47% of baseline smokers and 39% of nonsmokers had rapid decline in FEV 1 , defined using a common cutoff of .40 mL/yr. Although this difference was not statistically significant (P = 0.09), these frequencies of rapid decline are slightly higher than the frequencies of rapid decline seen in non-HIV cohorts such as the ECLIPSE observational cohort of patients with COPD, where 38% had an FEV 1 decline .40 mL/yr 27 and the Lovelace Smokers Cohort of current and former smokers in New Mexico where 25% had an FEV 1 decline .40 mL/yr. 28 We found larger differences when analyzing more extreme definitions of rapid decline in FEV 1 such as .50 mL/yr (P = 0.06) and .60 mL/ yr (P = 0.002).
Lung function decline is admittedly a surrogate outcome for the clinical outcome of COPD. However, using a clinical outcome of COPD is challenging, due to the long duration typically required to develop COPD, especially in a young cohort such as START, where baseline median age was only 36 years. Despite these limitations, we found a trend toward more incident COPD in smokers compared with nonsmokers (9.7% vs 5.8%; P = 0.06) over a median of 3.9 years of follow-up. Using the fixed-ratio definition of COPD (FEV 1 /FVC , 0.7), we found a smaller difference (7.7% vs 5.0%; P = 0.108). This is not unexpected, as using a fixed ratio is known to underestimate the occurrence of COPD in younger patients, such as the participants in our cohort. 25 Although there are limited data exploring incident COPD among HIV-positive individuals, our findings are remarkably consistent with a single-center study in Denmark where 63 HIV-positive patients underwent baseline and repeat spirometry over an average of 4.5 years. The prevalence of COPD increased from 20% to 33% (13% increase) among smokers and from 0% to 6% (6% increase) among nonsmokers. 16 In addition to the increased risk of COPD, decreased lung function has been associated with increased mortality in HIV-positive individuals and in the general population. 15, [30] [31] [32] Some have postulated that the effects of smoking on lung function decline might be more pronounced in HIV compared with non-HIV populations, perhaps due to HI, rendering the lung more susceptible to abnormal responses to environmental noxious stimuli such as smoking. [11] [12] [13] Several studies have estimated that smoking increases FEV 1 decline between 14 and 29 mL/yr in non-HIV COPD patient cohorts 26, 27, 33 and between 4 and 27 mL/yr in general population cohorts. [34] [35] [36] Non-HIV cohorts of lung function decline are generally older in age, although the effects of smoking do not seem to vary significantly depending on age. For example, in a cohort study of approximately 4500
Norwegian participants between 15 and 54 years of age at baseline, the effect of smoking on FEV 1 decline ranged from 4.4 to 18.8 mL/yr depending on sex and smoking intensity. 35 We found a mean difference in FEV 1 decline of 13-18 mL/yr (depending on the analytic method applied) between HIVpositive smokers and nonsmokers, which is very similar to the estimated effects of smoking on lung function decline in these non-HIV cohorts. However, a direct comparison between FEV 1 decline in our HIV-positive cohort and other cohorts is limited by the older average age of participants in the non-HIV studies cited above.
The SGRQ is a patient-reported outcome used to evaluate respiratory health status, and the consensus minimal clinical important difference is 4 points in the total SGRQ score. 29 We found a statistically and clinically insignificant difference in total score changes between smokers and nonsmokers. The SGRQ symptom component showed a statistically significant difference of 3.2 points, favoring nonsmokers, but the minimal clinically important differences for subscores have not been determined. Although we found no difference in total SGRQ score changes between smokers and nonsmokers, our study FIGURE 2. FEV 1 slopes (point estimates and 95% CIs) by categorical smoking status adjusted for treatment group, age, sex, race, baseline COPD, and region. Continuous smokers self-reported smoking at every study visit; intermittent smokers reported different smoking status at 2 or more visits; and sustained nonsmokers reported not smoking at each study visit. Rapid decline in lung function is often defined using an FEV 1 slope of steeper than 240 mL/yr, although there is no consensus definition. Presented are other more extreme definitions using 250 mL/yr and 260 mL/yr definitions. *Participant slopes were estimated from linear regressions of FEV 1 on visit. P values are from logistic regressions comparing smokers and nonsmokers, adjusted for the treatment group (immediate vs deferred treatment arm of START), age, sex, race, baseline COPD, and region. Higher scores indicate worse respiratory health status. The minimal clinically important difference is 4.0 points for the total score; domain scores have no established minimal clinically important differences.
*Changes from baseline in the SGRQ were modeled using a repeated-measures (months 12, 24, 36, 48, 60, and 72) mixed model for change in score from baseline, adjusted for baseline score. participants had generally good lung function and good respiratory health status at study entry (an average SGRQ total score of 7.2 on a scale of 0-100, where higher scores indicate worse respiratory health status). Therefore, we may have had insufficient time to detect clinically meaningful differences.
Our study has a number of important limitations. We enrolled a relatively young cohort of patients with relatively short average duration of known HIV (1.2 years) and all had CD4 counts .500 cells per mm 3 at study entry. Therefore, we are not able to extrapolate these findings to older HIVpositive patients who smoke nor those who present with more advanced HIV. Although our average follow-up time of nearly 4 years is within the 3-5 years used in most studies seeking to modify FEV 1 slope, 26, 33, 37 we acknowledge that longer follow-up time might lead to different slope estimates and would improve power for outcomes such as incident COPD. We did not biochemically confirm smoking status, so misclassification in either direction was possible. However, previous work has shown that self-reported smoking is generally a reliable indicator of actual smoking status. 38 Our data quantify the effect of tobacco smoke exposure on lung function decline, but not the effect of other inhalational exposures (eg, biomass fuels, kerosene lamps, and occupational dusts) that might additionally impact lung function decline, particularly in low-to-middle income countries. 39, 40 In addition, the number of female smokers in our sample was small (n = 19), so our conclusions may not be applied with complete confidence to female HIV-positive smokers.
Our study also has several strengths. We enrolled participants from 80 sites in 20 countries, making our results generalizable across a wide spectrum of the global HIV epidemic. FEV 1 slope was the primary outcome of the original randomized substudy design, and therefore, we exerted significant efforts to standardize spirometry equipment, training protocols, and quality control. Although our participants' average short duration of HIV and high CD4 counts at study entry is a limitation, it is also a strength, due to the avoidance of potentially confounding effects of opportunistic infections and profound immunosuppression on lung function. Finally, to the best of our knowledge, our collection of longitudinal lung function data in 915 HIV-positive persons followed for an average of nearly 4 years is the largest to date in a contemporary HIV cohort.
Our observational study is unable to prove that smoking cessation reduces lung function decline in the same manner as has been shown using a randomized trial design in patients with COPD. 26 Nevertheless, our data are compelling, and the observation that over one-third of baseline smokers reported not smoking at one or more follow-up visits suggests that smoking behaviors are not static and efforts at smoking cessation can and should be supported.
CONCLUSIONS
HIV-positive individuals who smoke have a faster rate of lung function decline compared with those who do not smoke. Our results underscore the need for a better understanding of how to best support smoking cessation among HIV-positive populations.
